APRI - Apricus Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Apricus Biosciences, Inc.

11975 El Camino Real
Suite 300
San Diego, CA 92130
United States

IndustryDrug Manufacturers - Other
Full Time Employees15

Key Executives

Mr. Richard W. PascoeChief Exec. Officer, Principal Accounting Officer, Sec. and Director500.23kN/A54
Mr. Brian T. DorseyChief Devel. Officer and Sr. VP331.89kN/A49
Mr. Neil C. MortonChief Bus. Officer and Sr. VP286.81kN/A42
Ms. Kelly DeckExec. Director of Fin.N/AN/AN/A
Ms. Mary NaggsVP and Gen. CounselN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of product candidates in the areas of urology and rheumatology. Its lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. The company also engages in developing RayVa, which is in Phase 2 development for the treatment of Raynaud's Phenomenon associated with scleroderma; and Fispemifene, a tissue-specific selective estrogen receptor modulator for the treatment of secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. It operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.

Corporate Governance

Apricus Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.